AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that it has initiated the efficacy analyses of its ADVEXIN® Phase 3 study. The efficacy evaluation of the study will incorporate the prospective analyses of patients defined by clinical and molecular prognostic biomarkers, including abnormal p53 protein levels. Abnormality of the p53 tumor suppressor is one of the most common and fundamental molecular defects in cancer. The Phase 3 study compares ADVEXIN p53 therapy versus methotrexate in patients with recurrent head and neck cancer. The prospective efficacy assessment of the randomized, controlled clinical trial is based upon analyses of prognostic biomarkers and clinical outcome.
